Multiple Sclerosis. Multiple sclerosis
Conditions
Interventions
Intervention group: Taking a reduced dose (500 mg or one vial) of rituximab once every 6 months.
Sponsors
Hamedan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 90 Years
Inclusion criteria
Inclusion criteria: Confirm diagnosis of RRMS History of rituximab use History of adequate response to rituximab
Exclusion criteria
Exclusion criteria: Rejecting the diagnosis of RRMS The patient's need to change the type of medication taken during the study Urgent need to increase the dose of the drug during the study A sharp increase in the risk of recurrence of symptoms during the period of reducing the dose of the drug used.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The human CD19 antigen is a 95 kd transmembrane glycoprotein belonging to the immunoglobulin superfamily. CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells. CD19 is critically involved in establishing intrinsic B cell signaling thresholds through modulating both B cell receptor-dependent and independent signaling. Timepoint: 6 months and 1 year after the start of the therapeutic intervention. Method of measurement: CD19+ Bcell population. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKimia Etemadi
Hamedan University of Medical Sciences
Outcome results
None listed